Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

ΑMT: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
← Older editNewer edit →
>Josikins
>Josikins
No edit summary
Line 84: Line 84:
*'''[[Effect::Auditory distortion|Distortions]]'''
*'''[[Effect::Auditory distortion|Distortions]]'''
*'''[[Effect::Auditory hallucinations|Hallucinations]]'''
*'''[[Effect::Auditory hallucinations|Hallucinations]]'''
===Experience reports===
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
{{#ask:[[Category:Experience]][[Category:AMT]]|format=ul|Columns=1}}
Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_AMT.shtml Erowid Experience Vaults: AMT]


==Toxicity and harm potential==
==Toxicity and harm potential==

Revision as of 15:42, 6 December 2016

ΑMT
Chemical Nomenclature
Common names AMT, αMT, Indopan
Substitutive name α-Methyltryptamine, alpha-methyltryptamine
Systematic name 1-(1H-indol-3-yl)propan-2-amine
Class Membership
Psychoactive class Entactogen / Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Threshold 5 mg
Light 10 - 25 mg
Common 25 - 40 mg
Strong 40 - 60 mg
Heavy 60 - 80 mg
Duration
Total 13 - 15 hours
Onset 60 - 180 minutes
Peak 4 - 6 hours
After effects 1 - 5 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Alcohol
Caffeine
Cannabis
2C-T-x
2C-x
5-MeO-xxT
Amphetamines
Cocaine
DOx
DXM
MAOIs
MDMA
Mescaline
MXE
25x-NBOMe
PCP
SSRIs
Tramadol
Summary sheet: AMT

α-Methyltryptamine (αMT, AMT, Indopan) is a psychedelic, stimulant, and entactogen drug of the tryptamine class.[1] It was originally developed as an antidepressant by workers at a Michigan pharmaceutical manufacturing company known as Upjohn in the 1960s.[2] In the 1960's, AMT was prescribed in 5 - 10 milligram doses as an antidepressant in the Soviet Union under the trade name Indopan.[3]

Erowid has received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) AMT ingestion."[4] There is one reported death from AMT which was reported in February 2003 by the Miami-Dade County Medical Examiner Department, but it is not known how much was taken.[5]

Chemistry

General formula of a tryptamine molecule

AMT or α-Methyltryptamine is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. AMT is substituted at the alpha carbon Rα of its tryptamine backbone with a methyl group. AMT is found in freebase form as a racemate of its (R-) and (S-) enantiomers.[6]

Pharmacology

Main article: Serotonergic psychedelic

AMT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist.

AMT also acts as a releasing agent of serotonin, noradrenaline, and dopamine.[7][8] It also acts as a very weak, non-selective RIMA in-vitro[9] and in-vivo.[10], but this is unlikely to be very significant (if at all) with typical doses.

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

The physical effects of this drug may be overly intense for those who are not already experienced with psychedelics.

  • Spontaneous tactile sensations - AMT's "body high" can be described as an intense and constant all-encompassing sensation. In comparison to other psychedelics, this sensation does not manifest itself in the form of a continuously shifting tingling sensation that travels up and down the body spontaneously; it is instead felt as an extended, unchanging activation of every nerve ending on the body that lasts throughout the entire duration of the trip. This continuous sensation is immensely pleasurable but can become overwhelmingly intense and almost a burden at higher levels.
  • Stimulation - In terms of its effects on the physical energy levels of the tripper, AMT is very stimulating, resulting in jaw clenching and a shakiness and unsteadiness of the hands. The stimulation encourages trippers to move around, run, dance, climb or generally engage in physical activities. In comparison, other more commonly used psychedelics such as psilocybin are generally sedating and relaxed.
  • Difficulty urinating - A slight difficulty urinating is occasionally present.
  • Headaches - Many people report headaches towards the end of the experience
  • Increased blood pressure
  • Increased heart rate
  • Increased perspiration
  • Nausea - In terms of the physical discomfort experienced on this substance, moderate to extreme nausea is almost consistently reported when consumed at any dosage. This either passes once the tripper has vomited or gradually fades by itself as the peak sets in.
  • Pupil dilation
  • Temperature regulation suppression

Cognitive effects

In comparison to more traditional psychedelics such as LSD, DMT and Psilocin, the AMT head space is described as not nearly as deep, insightful or profound.

The total sum of these cognitive components regardless of the setting generally includes:

Visual effects

The visual effects of AMT are mostly present only when large doses have been consumed and are proportionally mild in comparison to the intensity of its accompanying cognitive and physical effects when compared to substances such as LSD and psilocin.

Enhancements

Distortions

Geometry

The visual geometry that is present throughout this trip can be described as more similar in appearance to that of Psilocin and 2C-E than LSD. At lower levels it can appear to be bland and simplistic in complexity but becomes equal in terms of intricacy and depth to that of any of the classical psychedelics at higher dosages. It can be comprehensively described with its variations as intricate in complexity (at heavy dosages), abstract in form, organic in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, equal in soft and sharp edges, small in size, fast in speed, smooth in motion, equal in round and angular corners, non-immersive in depth, and consistent in intensity. At higher dosages, the visual geometry is significantly more likely to result in states of Level 8B geometry over Level 8A.

Hallucinatory states

  • Transformations
  • Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - This particular effect is uncommon during the first half of the trip but capable of manifesting itself towards the end of the experience, particularly if sleep deprivation starts to take its toll due to the abnormally long duration. The internal hallucinations are more common within dark environments and can be comprehensively described through their variations as lucid in believability, fixed in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.

Auditory effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

Main articles: Research chemicals § Toxicity and harm potential & Responsible use § Hallucinogens

As a powerful monoamine reuptake inhibitor, AMT can be dangerous when taken in excessive doses or when combined with drugs such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of serotonin and dopamine. There is one reported death from AMT, but it is not known how much of the drug was taken.[5] Erowid states that they have received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) AMT ingestion."[4]

The toxicity and long-term health effects of recreational AMT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because AMT is a research chemical with very little history of human usage. Anecdotal evidence from people who have tried AMT within the psychedelic community suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is worth noting that AMT's analogue αET has been shown to produce long-lasting serotonergic neurotoxicity at very high doses.[11] It is possible that AMT could cause the same neurotoxicity at high dosages or with repeated long-term use.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

AMT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of AMT are built almost immediately after ingestion. After that, it takes about Time to half tolerance::1 week for the tolerance to be reduced to half and Time to zero tolerance::2 weeks to be back at baseline (in the absence of further consumption). AMT presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of AMT all psychedelics will have a reduced effect.

Dangerous interactions

Deaths from AMT are rare[4][5] but, as a powerful monoamine reuptake inhibitor (MRI), injury could occur when excessive doses are taken or when it is taken with drugs such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine.[12]

  • Australia: Sale and possession of AMT is illegal.
  • Germany: Sale and possession of AMT is illegal.
  • Greece: Sale and possession of AMT is illegal.
  • Japan: Sale and possession of AMT is illegal.
  • Russia: Sale and possession of AMT is illegal.
  • Sweden: Sale and possession of AMT is illegal.[13]
  • USA: AMT is a Schedule I drug.[14]
  • UK: AMT is a Class A drug and the sale and possession are illegal. See "the Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014"[15]
  • Canada: Canada has no mention of this substance in the Controlled Drugs and Substances Act.[16]
  • Latvia: AMT is a Schedule I drug.[17]

See also

References

  1. ↑ Erowid Online Books : TIHKAL - #48 a-MT | http://www.erowid.org/library/books_online/tihkal/tihkal48.shtml
  2. ↑ US Patent 3296072 - Method of Treating Mental Depression
  3. ↑ AMT's TiHKAL entry by Alexander Shulgan (IsomerDesigns) https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=48
  4. ↑ 4.0 4.1 4.2 AMT (Alphamethyltryptamine, IT-290) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/amt/amt_death.shtml
  5. ↑ 5.0 5.1 5.2 Boland DM, Andollo W, Hime GW, Hearn WL. “Fatality due to acute alpha-methyltryptamine intoxication”. J Anal Toxicol. 2005 Jul-Aug;29(5):394-7. | https://www.erowid.org/references/refs_view.php?ID=6603
  6. ↑ http://isomerdesign.com/PiHKAL/read.php?id=48
  7. ↑ The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(06)01381-1
  8. ↑ In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes | https://www.jstage.jst.go.jp/article/bpb/30/12/30_12_2328/_article
  9. ↑ Studies of Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase II. Inhibition by α-Methylated Substrate-Analogue Monoamines, α-Methyltryptamine, α-Methylbenzylamine and Two Enantiomers of α-Methylbenzylamine | https://www.jstage.jst.go.jp/article/jphs1951/41/2/41_2_191/_article
  10. ↑ THE EFFECT OF THREE TRYPTAMINE DERIVATIVES ON SEROTONIN METABOLISM IN VITRO AND IN VIVO | http://jpet.aspetjournals.org/content/127/2/110.short
  11. ↑ Reduction in brain serotonin markers by α-ethyltryptamine (Monase) (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/001429999190686K
  12. ↑ Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
  13. ↑ Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
  14. ↑ Drug Enforcement Administration | http://webcache.googleusercontent.com/search?q=cache:http://www.deadiversion.usdoj.gov/drug_chem_info/amt.pdf
  15. ↑ the Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014 | http://www.legislation.gov.uk/uksi/2014/3271/article/4/made
  16. ↑ CSDA | http://isomerdesign.com/Cdsa/schedule.php?structure=C
  17. ↑ Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) | http://likumi.lv/doc.php?id=121086
Retrieved from "http://psy.st/w/index.php?title=ΑMT&oldid=75353"